The traditional paper-based process of obtaining patient consent for participation in clinical trials, as well as the institutionally-based ethics approval process, presents ongoing challenges across the clinical research landscape compromising study start-up and leaving participants poorly informed and unengaged.
This webinar will focus on initiatives designed to reduce the redundancy in clinical trials oversight and make information more readily accessible to the public in order to create a better understanding of the expectations, risks and benefits of participation in research.
Key discussion points include:
- Is the current institutionally-based ethics review process efficient and acceptable or should it be changed?
- Will patients perceive threats to their privacy, jeopardizing their willingness to participate in clinical trials? Case study: Pharmacogenetic studies
- A new approach to engage participants through a Virtual Consent Platform
Ronald Heslegrave, Ph.D. Corporate Chief of Research William Osler Health System
Ronald Heslegrave is currently the Chief of Research at William Osler Health System in Toronto, Ontario, Canada. In this role he is responsible for building a program of research designed to strenghthen our capacity to conduct clinical trials. Moreover, the corporate research plan is to leverage our unique communities to drive the discovery of innovative practices and build an evidence base in support of sustainable healthcare transformation and the delivery of patient-inspired care.
Previously, he was a Senior Scientist in Research Ethics at the University Health Network, University of Toronto where his interest is in new models of ethics review oversight and developing new process for protecting and informing participants of research. In late 2011, he was appointed as the Inaugural Executive Director of the newly formed non-profit corporation in Canada called Clinical Trials Ontario supported by the Ministry of Economic Development and Innovation. This government-supported initiative which had the mandate to make the Province of Ontario a preferred location for global clinical trials. In this role he established the governance structure of the corporation, its mandate, a 5-year strategic plan, and acquired funding from the government to support the Corporation.
Prior to his current appointment and his work as an Executive Director, he has Chaired Research Ethics Boards in Canada for over 20 years in institutions that support research from areas such as cardiovascular, neurosurgical, organ transplantation, obstetrics and gynecology and especially specialized institutions in cancer, psychiatric care, geriatric and community care. In 2003 he initiated, established and served as the inaugural Chair for 8 years of the Research Ethics Board for multi-centre oncology clinical trials in Ontario.
Dr. Heslegrave was also a member a Canadian Expert Panel on Scientific Integrity and has spoken on this topic at the International Congresses on Research Integrity. He is currently the ethics delegate to the Institute of Cancer Research (CIHR). He has been an International Consultant to NIH, Oxford University, Wellcome Trust and the Ministry of Health in Vietnam and a national consultant on streamling the ethics review process in Canada.
Who Should Attend?
Directors, Managers, Heads of, Officers, Scientists, and Specialists in:
- Pharma and Biotech
- Contract Research Organizations
- Site Management Organizations
- Contract Manufacturing Organizations
- Research Institutions/Universities
- Institutional Review Boards/Research Ethics Boards
- Government, Regulatory Groups
- Patient Advocacy Groups
- Patient Service and Clinical Solutions Providers
Led by global industry thought leaders, each eCongress is a month-long webinar series, at your fingertips, which delivers practical, real-world insights and solutions to some of your industry’s biggest challenges.
Offered in a convenient, interactive and timely format, each eCongress is free to attend and highlights best practices, case studies and regulatory updates with the goal of facilitating proactive discussion and offering timely solutions around key industry issues.